Health Care·Life Sciences Tools & Services·$8.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.87 | N/A | +9.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.87 | N/A | +9.71% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management is optimistic about the company's performance, citing strong product demand. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in key product lines.
They expressed confidence in maintaining growth despite market challenges.
Bio-Techne Corp reported a better-than-expected EPS, indicating solid earnings performance. However, the stock fell 2.62% in reaction, which may reflect investor concerns about the lack of revenue data and future guidance. The cautious tone from management may have also contributed to the stock's decline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 3, 2010